Front Range Pharmaceuticals Receives FDA Clearance for Long COVID Phase 2 Trial

Front Range Pharmaceuticals has secured FDA clearance for its Investigational New Drug (IND) application for FRP-003. This approval allows the company to initiate a Phase 2 clinical trial for adults experiencing persistent fatigue due to Long COVID. The trial aims to evaluate the efficacy of FRP-003, potentially addressing a significant unmet medical need for individuals suffering from the lingering effects of the virus.